SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-108696
Filing Date
2022-04-19
Accepted
2022-04-19 07:30:56
Documents
18
Period of Report
2022-04-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d349814d8k.htm   iXBRL 8-K 38481
2 EX-1.1 d349814dex11.htm EX-1.1 209496
3 EX-4.1 d349814dex41.htm EX-4.1 64373
4 EX-5.1 d349814dex51.htm EX-5.1 12009
5 EX-99.1 d349814dex991.htm EX-99.1 9592
9 GRAPHIC g349814g0415082326781.jpg GRAPHIC 3703
10 GRAPHIC g349814g0415215429073.jpg GRAPHIC 2240
  Complete submission text file 0001193125-22-108696.txt   558687

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA inzy-20220414.xsd EX-101.SCH 2857
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20220414_lab.xml EX-101.LAB 18738
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20220414_pre.xml EX-101.PRE 11708
12 EXTRACTED XBRL INSTANCE DOCUMENT d349814d8k_htm.xml XML 3463
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 22833472
SIC: 2834 Pharmaceutical Preparations